Xing-Jie Liang, National Center for Nanoscience and Technology, Beijing, China
Dr. Xing-Jie Liang got Ph.D. at National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences. He finished his postdoc with Dr. Michael M. Gottesman, member of NAS and Deputy Director of NIH, for 5 years at Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health. Then he worked as a Research Fellow at Surgical Neurology Branch, NINDS, NIH. Dr. Liang is currently a principal investigator at Center for Excellence in Nanoscience, Chinese Academy of Sciences. As current president of Chinese Association of Nanobiology, he is the elected Fellow of American Institute for Medical and Biological Engineering (AIMBE) and Faculty Member of F1000 Research (Pharmacology & Drug Delivery). Dr. Liang has successfully developed “Injectable Nanomicelle Powder with Irinotecan” approved with CFDA and transferred NDA to pharmaceutical industry for clinical trials.
His research interests are in elucidating mechanisms to improve drugability and nanomedicinal bioavailability by nanotechnology in vitro and in vivo, and novel strategies to increase therapeutic efficiency on cancers and infective diseases. Developing drug delivery strategies for prevention/circumvent of clinical adaptive treatment tolerance (ATT) is current program ongoing in Professor Liang’s lab based on the understanding of basic physio-chemical and biological processes of nanomedicine.